FDMT
4D Molecular Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.29
+1.24%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +12.2%
- EBIT
- +10.5%
- EPS
- +22.9%
- Free cash flow
- +7.7%
- Operating cash flow
- +6.2%
Forward estimates
Based on analyst estimates
- Revenue
- -82.2%
- EBITDA
- -55.4%
- EPS
- -53.9%
Three-year CAGR
- Revenue
- +200.9%
- EBITDA
- +14.1%
- EBIT
- +15.1%
- Net income
- +12.9%
- EPS
- +18.8%
- Free cash flow
- +21.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026